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ClearanceSenile amyloid plaques are one of the diagnostic hallmarks of Alzheimer's disease (AD). However, the severity of
clinical symptoms of AD is weakly correlatedwith the plaque load. AD symptoms severity is reported to bemore
strongly correlated with the level of soluble amyloid-β (Aβ) assemblies. Formation of soluble Aβ assemblies is
stimulated by monomeric Aβ accumulation in the brain, which has been related to its faulty cerebral clearance.
Studies tend to focus on the neurotoxicity of speciﬁc Aβ species. There are relatively few studies investigating
toxic effects of Aβ on the endothelial cells of the blood–brain barrier (BBB). We hypothesized that a soluble Aβ
pool more closely resembling the in vivo situation composed of a mixture of Aβ40 monomer and Aβ42 oligomer
would exert higher toxicity against hCMEC/D3 cells as an in vitro BBB model than either component alone. We
observed that, in addition to a disruptive effect on the endothelial cells integrity due to enhancement of
the paracellular permeability of the hCMEC/D3 monolayer, the Aβmixture signiﬁcantly decreased monomeric
Aβ transport across the cell culture model. Consistent with its effect on Aβ transport, Aβmixture treatment for
24 h resulted in LRP1 down-regulation and RAGE up-regulation in hCMEC/D3 cells. The individual Aβ species
separately failed to alter Aβ clearance or the cell-based BBB model integrity. Our study offers, for the ﬁrst time,
evidence that a mixture of soluble Aβ species, at nanomolar concentrations, disrupts endothelial cells integrity
and its own transport across an in vitro model of the BBB.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is the most common cause of irreversible
dementia among the elderly with a rapidly increasing socioeconomic
impact [1]. During the last decade, amyloid- and tau-related neuropa-
thologies were considered as the main underlying causes of neurode-
generation, cognitive decline and memory loss associated with AD
[2,3]. Amyloid-β (Aβ) peptides are derived from a minor pathway of
proteolytic processing of the amyloid-β precursor protein (APP). In
AD, amyloid peptides, mainly Aβ40 and Aβ42, accumulate in the paren-
chymal tissue and the vasculature of cortical and hippocampal regions
of the brain where they assemble and form insoluble plaques [4].-β; APP, amyloid-β precursor
nzyme; LRP1, low density lipo-
P-glycoprotein; RAGE, receptor
acid
rmaceutical Science, School of
ille Dr., Monroe, LA 71201, USA.Aβ has multiple different assembly states ranging frommonomer to
insoluble plaque and all of these states have been identiﬁed in the brain
of AD patient [5,6]. Twomain pools of Aβ have been distinguished in the
brain of AD patients, a soluble pool that consists of a mixture of Aβ
monomers and soluble oligomers, and an insoluble pool of insoluble
oligomers and higher order histologically prominent insoluble Aβ ﬁbrils
[7]. Increasing evidence indicates that soluble pool of Aβ is more biolog-
ically active than the insoluble Aβ ﬁbrils [8,9]. Moreover, a comparison
of pathology with clinical diagnosis of AD brains found a weak correla-
tion between Aβ plaque load and the progression of AD symptoms, in
contrast to a better correlation of the soluble pool of Aβwith AD clinical
severity [8,10,11].
The soluble Aβ pool consists of multiple species of Aβ; however,
Aβ40 and Aβ42 are the most abundant, readily identiﬁable, and are con-
sidered the most important components contributing to the pathology
of AD. Aβ40 is themost abundant Aβ species in the brain of AD patients,
however, Aβ42 is the main peptide involved in the soluble oligomers
due to its high propensity to aggregate [12]. Moreover, Aβ42 oligomers
that are initially formed act as a seed that can accelerate the
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several-fold higher than Aβ42 [6].
In late-onset “sporadic” AD, extensive studies have suggested that
reduced clearance of Aβ from the brain across the blood–brain barrier
(BBB) to the periphery signiﬁcantly contributes to its accumulation
in the brain [13]. P-glycoprotein (P-gp) and low-density lipoprotein
receptor-related protein-1 (LRP1) at the BBB have been reported to
play important roles in Aβ clearance from the brain to the blood
[14–16]. On the other hand, the receptor for advanced glycation end
products (RAGE) mediates inﬂux of Aβ from blood to brain [17]. In ad-
dition to clearance via transport across the BBB, monomeric Aβ is sub-
jected to proteolytic degradation by insulin degrading enzyme (IDE)
and neprilysin (NEP) that are expressed in different cellular component
of the brain including BBB endothelium [18–22]. Previous in vitro and
in vivo studies have demonstrated reduced expression of P-gp in brain
capillaries treated with Aβ40 or Aβ42 monomers, or Aβ42 oligomers
[23,24]; LRP1 and RAGE gene expressions were reduced in the brain of
wild type mice treated with human Aβ42 monomers but not with
Aβ40 monomers [25]. However, none of these studies investigated the
effect of Aβ treatment on its own clearance. To our knowledge, studies
investigating the effect of more physiologically and pathologically rele-
vant Aβ peptide composition on the clearance of Aβmonomers across
the BBB and its degradation are lacking.
Several pathological alterations in BBB function have been observed
in AD patients. Disrupted capillary integrity, loss of controlledmolecular
transport, and uncontrolled solute exchange are among these patholog-
ical alterations [26]. Furthermore, available studies have reported loss of
tight junction proteins necessary to restrict paracellular transport be-
tween blood and brain, which contributes to the pathogenesis of AD
[27]. Accumulating evidence suggests that Aβ has disruptive effects on
the integrity of the BBB [24,28–30]. In addition, about 80–90% of AD pa-
tients develop cerebral amyloid angiopathy (CAA) that is characterized
by Aβ accumulation in brain blood vessel walls and associated with
compromised BBB function [31]. Available studies have shown that in-
creased levels of soluble Aβ affect integrity of BBB endothelial cells by
reducing the expression and re-localization of tight junction proteins
[28–30]. However,most of these studies,which investigated the toxicity
of speciﬁc species of soluble Aβ isoforms against BBB endothelium used
high non-physiological or even pathological Aβ concentrations. Thus,
evaluating the effect of Aβ on BBB endothelial cells integrity in the pres-
ence ofmore than oneAβ species at nanomolar concentrations provides
a more biologically relevant approach to clarify the pathological
changes that are associated with Aβ in AD. Accordingly, in this study,
we hypothesized that Aβ mixture consisting of nanomolar levels of
both Aβ40 monomer and Aβ42 oligomer exerts greater toxicity against
endothelial cells of the BBB than the individual species. To test this
hypothesis, the human brain endothelial cell line hCMEC/D3, as an
in vitro cell-based BBBmodel,was used to study the effect of Aβmixture
on the transport of Aβmonomer and Aβ toxic effect on BBB endothelial
cells.
2. Methodology
2.1. Preparation and characterization of synthetic amyloid-β mixture
Solutions of synthetic Aβ40 and Aβ42 peptides (AnaSpec, Inc.; CA)
were prepared by suspending in 1, 1, 1, 3, 3, 3-hexaﬂuoro-2-propanol
(HFIP) (Sigma-Aldrich, MO) each at a concentration of 1 mM and incu-
bated for 1 h at room temperature for complete solubilization. Aβ solu-
tions were aliquoted, HFIP was evaporated overnight and the peptides
stored at−20 °C as an HFIP ﬁlm. For Aβ40 monomer, HFIP ﬁlmwas dis-
solved inmedia and used immediately for cell treatment or for prepara-
tion of Aβmixture as described below. Aβ42 oligomer was prepared as
described previously [32]. Brieﬂy, aliquoted Aβ42 peptide HFIP-ﬁlm
was suspended in anhydrous DMSO (Sigma-Aldrich, MO) to a ﬁnal con-
centration of 5mM, vortexmixed for 1min. DMSO solution of Aβ42 wasdiluted with phenol red-free F-12 cell culture media (Gibco, NY) to a
concentration of 100 μM, vortexed for 1 min and incubated at 4 °C
for 24 h. At the end of incubation period, the Aβ42 oligomer solution
was centrifuged at 14,000 rpm, 4 °C for 10 min. The supernatant was
fractionated at room temperature using size exclusion chromatography
(SEC) to separate oligomers from monomers. Two hundred microliters
of the supernatant was injected onto a sephadex G-75 column and elut-
edwith 15mlmedia atﬂow rate of 0.5 ml/min. Twenty-four fractions of
0.5mlwere collected after the elution of the ﬁrst 3 ml. Aβ42 oligomer in
each fraction was assessed by sandwich ELISA as described previously
[33]. 6E10 (aa. 3–8 human Aβ sequence) monoclonal antibody
(Covance Research Products, MA) was coated at 5 μg/ml concentration
(100 ng/well) on an Maxisorp ELISA plate (Thermo, NY) to capture
Aβ42 oligomer. Detectionwas achievedwithHRP-conjugated 6E10 anti-
body at 1 μg/ml (Covance Research Products, MA). Fractions that
contained Aβ42 oligomers were collected and used immediately after
proper dilution to the required concentration for cell treatment or for
preparation of Aβ mixtures. Aβ mixtures were prepared by mixing
Aβ40 monomers at concentrations 0, 50, 100 or 250 nM and Aβ42 oligo-
mers at concentrations 0, 25, 50, or 100 nM. Treatment concentrations
of Aβ40 monomer, Aβ42 oligomer and Aβ mixtures were measured
using western blot analyses. Forty microliters of the treatment solution
and Aβ standards (500, 250, 100, 50, 25 nM) were resolved on a 16%
Bis–Tris gel in 3-(N-morpholino) propanesulfonic acid buffer system
and transferred onto a 0.45 μm pore size nitrocellulose membrane
(Bio-Rad, CA). The membrane was blocked with 5% BSA in TBS buffer
(20 mM Tris–HCl, 150 mM NaCl pH 7.5) for 1 h and incubated with
6E10 antibody (1:1000 dilution in TBS buffer containing 5% BSA and
0.05% Tween-20) for 3 h at room temperature. For antigen detection,
the membranes were washed and incubated with HRP-labeled second-
ary anti-mouse (Santa Cruz, TX) at 1:5000 dilution. The bands were
visualized using a SuperSignal West Femto detection kit (Thermo
Scientiﬁc, IL). Quantitative analysis of the immunoreactive bands was
performed using a GeneSnap luminescent image analyzer (Scientiﬁc
Resources Southwest, TX), and band intensities weremeasured by den-
sitometry analysis. Band intensities were plotted against concentration
of standards and the concentration of treatment solution were interpo-
lated from the resulting calibration curve. For all experiments, Aβ42
oligomers and Aβmixtures were prepared in the same way described
above using Aβ standards purchased from the same manufacturer
(AnaSpec, Inc.).
2.2. Cell culture
Human brain endothelial cells (hCMEC/D3; kindly provided by
Dr. P.O. Couraud, Institute Cochin, Paris, France), passages 25–35, were
used as a representative model for human BBB. hCMEC/D3 cells were
cultured in EBM-2 medium (Lonza, MD) supplemented with 1 ng/ml
human basic ﬁbroblast growth factor (Sigma-Aldrich, MO), 10 mM
HEPES, 1% chemically deﬁned lipid concentrate (Gibco, NY), 5 μg/ml
ascorbic acid, 1.4 μM hydrocortisone, 1% penicillin–streptomycin and
5% of heat-inactivated FBS gold (GE Healthcare Life Sciences, PA). Cul-
tures were maintained in a humidiﬁed atmosphere (5% CO2/95% air)
at 37 °C and media was changed every other day.
2.3. Toxicity of synthetic amyloid-βmixture on hCMEC/D3 cells
MTT cytotoxicity assaywas performed to select sub-toxic concentra-
tions of Aβ preparations. hCMEC/D3 cells were seeded onto 24-well
plate and maintained as described above. At 70% conﬂuence, cells
were treated for 24 h with Aβ40 monomer, Aβ42 oligomers or mixtures
of Aβ40 monomer and Aβ42 oligomers at different concentrations. Aβ40
monomer concentration dependent toxicity against hCMEC/D3 cells
were studied at the concentrations 0, 50, 100 and 250 nM in the pres-
ence or absence of 50 nM Aβ42 oligomers. For Aβ42 oligomers concen-
tration dependent study, cells were treated with 0, 25, 50 and 100 nM
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ity assays (Trevigen, MD) were performed at the end of incubation pe-
riod with Aβ preparations as described previously [34].2.4. Effect of synthetic amyloid-β mixtures on hCMEC/D3 cells
monolayer integrity
The barrier integrity of hCMEC/D3 was evaluated by measuring 14C-
inulin ([carboxyl-14C]-inulin, M.W.: 5000 Da; American Radiolabeled
Chemicals, MO) permeation. Inulin is a marker for paracellular transport
across a cellmonolayerwhere its transendothelial transport across intact
hCMEC/D3 monolayer is greatly restricted [35]. To prepare hCMEC/D3
cell monolayers, transwell polyester membrane inserts, 6.5 mm diame-
ter with 0.4 μm pores (Corning, NY), were coated with rat tail collagen-
IV (150 μg/ml) for 90min at 37 °C. Cells were plated onto coated inserts
at a seeding density of 50,000 cells/cm2, medium was changed every
other day. Trans-epithelial electrical resistance (TEER) was measured
using an EVOM epithelial volt-ohmmeter with STX2 electrodes (World
Precision Instruments, FL). hCMEC/D3 cell monolayers were used for
Aβ40 transport and inulin permeation experiments on day 6 of culture
[21,35]. On day 6, the TEER value was measured and ranged from 35 to
40 Ω cm2 that is consistent with previously reported values for this cell
line [35]. Cells were treated for 24 h treatment with increasing concen-
tration of monomeric Aβ40 in the presence or absence of 50 nM Aβ42
oligomer or increasing concentration of Aβ42 oligomer with or without
100 nM monomeric Aβ40. At the end of treatment, apical to basolateral
14C-inulin permeation coefﬁcient was measured. For inulin permeation,Fig. 1. Preparation of Aβmixtures. Starting from synthetic Aβ42 monomer, a stable oligomer w
(B) SEC proﬁle of Aβ42 oligomers asmeasured by an oligomer-speciﬁc ELISA. Fractions 4–8 conta
ysis for puriﬁed Aβ42 oligomer, Aβmixture and a calibration curve of monomeric synthetic Aβ40
versus concentration calibration curve that was used to quantify Aβ concentrations.200 μl of fresh media containing 0.05 mM 14C-inulin was added to the
apical chamber and 800 μl of fresh media was added to the basolateral
chamber. Cells were maintained in a humidiﬁed atmosphere (5% CO2/
95% air) at 37 °C for the time course of the permeability experiment
(up to 2 h). Fifty microliter aliquots from the basolateral chamber were
collected at 15, 30, 45, 60, 90, 120 min and replaced with 50 μl of fresh
media to keep the volume of basolateral chamber unchanged and main-
tain constant osmotic pressure. Aftermixing sampleswith 5ml of scintil-
lation cocktail, 14C-inulin dpm was measured using a Wallac 1414
WinSpectral Liquid Scintillation Counter (PerkinElmer, MA). Concentra-
tions of 14C-inulin in basolateral side (in dpm/ml) were plotted versus
time. 14C-inulin permeation coefﬁcient (Papp in cm/s) was calculated
from the following equation [36]:
Papp¼ ΔQ=Δtð Þ= A  Coð Þ ð1Þ
where ΔQ/Δt is the linear appearance rate of the 14C-inulin in the
basolateral chamber, A is the surface area of the cell monolayer
(0.33 cm2) and Co is the initial concentration of 14C-inulin (dpm/ml).
2.5. Effect of synthetic amyloid-β mixtures on 125I-Aβ40 transport across
hCMEC/D3 cell monolayer
The transport of 125I-Aβ40 (PerkinElmer, MA) and 14C-inulin, as a
marker for paracellular diffusion, were measured across hCMEC/D3
monolayer after treatment with different Aβ preparations. hCMEC/D3
cell monolayers were seeded and maintained in transwell chambers
as described above. One day before conducting transport experiments,as prepared and fractionated by SEC. (A) A representative blot of crude Aβ42 oligomers.
ining oligomerswere collected for further analysis. (C) A representativewesternblot anal-
standards to adjust the concentration of each species for cell treatment. (D) Densitometry
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the presence or absence of 50 nM Aβ42 oligomer or increasing concen-
tration of Aβ42 oligomer with or without 100 nM monomeric Aβ40.
Basolateral to apical (B→ A) transport studies were then performed
as described previously [21]. In brief, the transport study was initiated
by removing media that contained Aβ mixture and addition of 800 μl
of fresh media containing 0.1 nM 125I-Aβ40 and 0.05 mM 14C-inulin to
the basolateral compartment. At the end of incubation period (6 h),
media from both compartments and cells were separately collected
for 125I-Aβ40 analysis and 14C-inulin measurement [21]. The transport
quotients of B → A (125I-Aβ40 CQB → A) transport were calculated
using the following equation [37]:
125I‐Aβ40 CQB→A ¼
125I‐Aβ40 in apical compartment
125I‐Aβ40 total
 !
14C‐inulin in apical compartment
14C‐inulin total
 ! ð2Þ
where 125I-Aβ40 total is the total intact cpm in the apical and basolateral
compartments, as well as cpm remaining in cells. 14C-inulin total is the
total inulin dpm in the apical and basolateral compartments. Trichloro-
acetic acid (TCA) precipitation [38] was used to measure the amount of
intact and degraded 125I-Aβ40. Total 125I-Aβ40 was determined by
counting sample radioactivity. Degraded 125I-Aβ40 was measured inFig. 2. Cell toxicity assays after treatment with Aβ preparations. (A) Concentration dependent M
Aβ42 oligomer. (B) Concentration dependentMTT cytotoxcity assay of 0, 25, 50 and 100 nMof A
as measured by MTT reduction to formazan were observed only after 24 h treatment with
(C) Microscopic images of cells after exposure to control media or Aβmixture (100 nM mono
of n = 3 independent experiments.the supernatant following precipitationwith TCA. Tomeasure degraded
125I-Aβ40, one volume of TCA (20%) was added to the sample, and then
samples were vortex mixed, incubated in ice for 30 min, and then cen-
trifuged at 14,000 rpm (4 °C) for 30 min. Following centrifugation, the
gamma radioactivity of the TCA supernatant containing degraded pep-
tide was measured using a Wallac 1470 Wizard Gamma Counter
(PerkinElmer,MA). The intact fractionwas calculated by subtracting de-
graded 125I-Aβ40 from total 125I-Aβ40.
2.6. Expression of P-gp, LRP1, RAGE, IDE and NEP in hCMEC/D3 cells
following amyloid-β treatments
Cells were seeded in 100 mm cell culture dishes (Corning, NY) at a
density of 1 × 106 cells per dish. The cells were allowed to grow to
70% conﬂuencybefore treatmentwith different Aβ preparations in a hu-
midiﬁed atmosphere (5% CO2/95% air) at 37 °C. Cells were treated for
24 h with control media, 100 nM monomeric Aβ40, 50 nM Aβ42 oligo-
mers ormixture of 100 nMmonomeric Aβ40 and 50 nMAβ42 oligomers.
At the end of treatment period, RIPA buffer containing complete mam-
malian protease inhibitormixture (Sigma-Aldrich,MO)was used to dis-
solve cells. Forwestern blot analysis of P-gp, LRP1, RAGE, IDE andNEP in
hCMEC/D3 cells after Aβ treatment, 25 μg of cellular protein was re-
solved on 8% Bis-tris gels in 3-(N-morpholino) propanesulfonic acid
buffer system and electrotransferred onto 0.45 μm nitrocellulose mem-
brane. Membranes were blocked with 2% BSA and incubated overnightTT cytotoxcity assay of 0, 50, 100 and 250 nM of monomeric Aβ40 with or without 50 nM
β42 oligomerwith orwithout 100 nMAβ40monomer. Signiﬁcant reductions in cell viability
250 nM monomeric Aβ40, 100 nM Aβ42 oligomer and their corresponding mixtures.
meric Aβ40 and 50 nM Aβ42 oligomers) for 24 h. The data are expressed as mean ± SEM
Fig. 3. Effect of Aβ preparations on the integrity of an hCMEC/D3monolayer model of the
BBB endothelium. Apical to basolateral 14C-inulin permeation across the hCMEC/D3 cell
monolayer was monitored for 2 h after 24 h treatment with different Aβ preparations at
sub-toxic nanomolar concentrations. (A) Schematic presentation of hCMEC/D3monolayer
shows the direction of inulin permeationwhen added to the apical side. (B) Concentration
dependent studies on the effect of Aβ40 monomer with or without 50 nM Aβ42 oligomer
on inulin permeation, and (C) Concentration dependent studies on the effect of Aβ42 olig-
omerwith orwithout 100 nMAβ40 monomer on inulin permeation. 14C-inulin permeaion
in the apical to basolateral direction was signiﬁcantly enhanced after treatment with Aβ
mixture of 100 nM Aβ40 monomer and 50 nM Aβ40 oligomer indicating the disruptive ef-
fect of this Aβmixture on the integrity of the hCMEC/D3 cells. Data representmean±SEM
from three independent experiments, * P b 0.05.
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Products, MA), LRP1 (Calbiochem, NJ), RAGE (Santa Cruz, TX), IDE
(Santa Cruz, TX), NEP (Calbiochem,NJ) or GAPDH (Santa Cruz, TX) at di-
lutions 1:200, 1:1500, 1:200, 1:200, 1:100 and 1:3000, respectively. For
antigen detection, the membranes were washed and incubated with
HRP-labeled secondary IgG antibody for P-gp, RAGE, NEP and GAPDH
(anti-mouse), LRP1 (anti-rabbit) and IDE (anti-goat) (Santa Cruz, TX)
at 1:5000 dilution. The bands were visualized and quantiﬁed as de-
scribed above. Three independent Western blotting analyses were car-
ried out for each treatment group.
2.7. Statistical analysis
Unless otherwise indicated, the data were expressed as mean ±
SEM. The experimental results were statistically analyzed for signiﬁcant
difference using two-tailed Student's t-test for 2 groups, and one-way
analysis of variance (ANOVA) for more than two group analysis. Values
of P b 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Characterization of Aβ preparations
To study the toxicity of Aβ species on hCMEC/D3 cells, Aβ40 mono-
mer and Aβ42 oligomers were ﬁrst prepared and characterized. These
Aβ specieswere selected because Aβ40 is themost abundant Aβ peptide
in the brains of AD patients, and soluble Aβ42 oligomers are the initial
seeds for forming higher order assemblies, and they have proved to
have high toxicity [6]. Fig. 1A and C conﬁrmed Aβ42 oligomers forma-
tion; oligomers include SDS-stable dimer, trimer, tetramer; no large
protoﬁbrils were detected. Fig. 1B shows a representative SEC proﬁle
where Aβ42 oligomers, as measured by a total oligomer-speciﬁc ELISA,
were detected in fractions 4–8. Subsequently, immunoblotting assay
was utilized to estimate the concentrations of both, the monomer and
oligomers. The concentrations of all Aβ species were calculated based
on a calibration curve of Aβmonomer standards (Fig. 1C and D).
3.2. Assessing toxicity of Aβ preparations against hCMEC/D3
Cell viability assays were performed initially to conﬁrm that Aβ
preparations used in the treatment of hCMEC/D3 cells were not toxic
at the applied concentrations after 24 h of treatment. MTT cytotoxicity
assay with hCMEC/D3 cells demonstrated that cell treatment did not af-
fect the viability of hCMEC/D3 after 24 h exposure to Aβ preparations
except at high concentrations of Aβ40 monomers and Aβ42 oligomers
added separately or as a mixture. MTT assay results from cells treated
with Aβ40 monomers at 50 and 100 nM, Aβ42 oligomers at 25 and
50 nM, or mixtures of these concentrations were comparable to control
treated cells (Fig. 2A and B). However, MTT assay showed that the via-
bility of hCMEC/D3 decreased by 14–17% following treatment with
250 nM Aβ40 monomer, mixture of 250 nM Aβ40 monomer and 50 nM
Aβ42 oligomer, 100 nMAβ42 oligomer andmixture of 100 nMAβ42 olig-
omer and 100 nM Aβ40 monomer (Fig. 2A and B). Thus, for permeation
studies of inulin and Aβ, high concentrations that induced toxicity were
excluded andonly sub-toxic concentrationswere used for cells treatment.
Fig. 2C demonstrates absence of morphological changes on hCMEC/D3
cells after 24 h treatment with Aβ mixture consisting of 100 nM Aβ40
monomers and 50 nM Aβ42 oligomers when compared to control.
3.3. Treatment of hCMEC/D3 cells monolayer with Aβ mixture increases
paracellular permeability
The integrity of the barrier formed by hCMEC/D3 cells grown on in-
serts after 24 h exposure to Aβ preparations was assessed bymeasuring
permeation of 14C-inulin across the cellmonolayer. After 24 h treatment
with 0, 50 and 100 nM Aβ40 monomer in the presence or absence of 25or 50 nMAβ42 oligomer, only Aβmixture of 100 nMAβ40monomer and
50 nMAβ42 oligomer disrupted themonolayer integrity and signiﬁcant-
ly increased apical to basolateral permeation of 14C-inulin across
hCMEC/D3 by 11–15% compared to control (p b 0.05; Fig. 3A and B).
On the other hand, treatments with Aβ species separately, or mixtures
at 50 nM each or 100monomer and 25 oligomer failed to change inulin
permeation (Fig. 3A and B).3.4. Treatment with Aβ mixture decreases 125I-Aβ40 transport across
hCMEC/D3 cell monolayer
Twenty-four hour treatment of hCMEC/D3 cells monolayer with
100 nM Aβ40 monomer or 50 nM Aβ42 oligomer added separately to
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apical side (representative for brain to blood clearance). However, sig-
niﬁcant reduction in 125I-Aβ40 transport from basolateral to apical side
(p b 0.05) was only observed following exposure of hCMEC/D3 cells to
a mixture of 100 nM Aβ40 monomer and 50 nM Aβ42 oligomer
(Fig. 4). In particular, this reduction in Aβ40 transport quotientwas a re-
sult of decreased transport of Aβ40 across the hCMEC/D3 cells (Supple-
mentary Fig. 1). Transport studies onmonomeric 125I-Aβ40 for 6 h across
hCMEC/D3 cells monolayer showed a signiﬁcant reduction in 125I-Aβ40
transport quotients (CQB → A) by 20–25% across cells treated with
100 nM Aβ40 monomer and 50 nM Aβ42 oligomer mixture; while a re-
duction trend in 125I-Aβ40 CQB→ Awas observedwith othermixtures in-
vestigated at different combined concentrations, this reduction was not
statistically signiﬁcant when compared to control treatment (Fig. 4).
Besides, treatment with all Aβ preparations for 24 h had no effect
on 125I-Aβ40 degradation as measured by TCA assay. The percentFig. 5. Degradation of 125I-Aβ40 by hCMEC/D3 cell monolayer after exposure to Aβ prepa-
rations. (A) % degradation of 125I-Aβ40 by hCMEC/D3 monolayer treated for 24 h with in-
creasing concentrations of Aβ40 monomer with or without 50 nM Aβ42 oligomers, and
(B) % degradation of 125I-Aβ40 by hCMEC/D3 monolayer treated for 24 h with increasing
concentrations of Aβ42 with or without 100 nM Aβ40 monomer. None of Aβ preparations
altered % degradation of 125I-Aβ40 after 24 h treatment. Data represent mean± SEM from
three independent experiments; * P b 0.05.
Fig. 4. Transport of 125I-Aβ40 across hCMEC/D3 cell monolayer after exposure to Aβ prep-
arations. (A) Schematic presentation of hCMEC/D3 monolayer shows the direction of
transport of 125I-Aβ40 added to the basolateral side. (B) Transport quotient CQB → A of
125I-Aβ40 across hCMEC/D3 monolayer treated for 24 h with increasing concentrations
of Aβ40 monomer with or without 50 nM Aβ42 oligomers, and (C) Transport quotient
CQB→ A of 125I-Aβ40 across hCMEC/D3monolayer treated for 24 hwith increasing concen-
trations of Aβ42 oligomers with or without 100 nM Aβ40 monomer. While Aβ mixture
of 100 nM Aβ40 monomer and 50 nM Aβ42 oligomer signiﬁcantly reduced CQB → A
of 125I-Aβ40, other Aβ preparations did not affect 125I-Aβ40 transport. Data represent
mean ± SEM from three independent experiments; * P b 0.05.degradation of 125I-Aβ40 in the media of hCMEC/D3 were similar for
all treatments with degradation % values in the range of 15.7–17%
(Fig. 5).
3.5. Aβ mixture differentially affects the expression of LRP1 and RAGE in
hCMEC/D3 cells but not P-gp and Aβ degrading enzymes
Given the important role of P-gp and LRP1 in the transport of Aβ
across the BBB, we determined the effect of Aβmixture (100 nM Aβ40
monomers and 50 nM Aβ42 oligomers) on the expression of these
proteins in hCMEC/D3 cells in order to explain the reduced transport
of Aβ40 across the monolayer. The results of western blot analysis fol-
lowing 24 h treatment demonstrated that the expression of P-gp in
hCMEC/D3 was not altered by Aβ40 monomers, Aβ42 oligomers, or Aβ
mixture treatments (Fig. 6A and B). However, treatment with Aβmix-
ture signiﬁcantly decreased the expression of LRP1 (P b 0.01). This re-
duction was not observed with Aβ40 monomers or Aβ42 oligomers
(Fig. 6A). Densitometry analysis of western blot bands showed a signif-
icant 20% reduction in the expression of LRP1 after treatment with Aβ
mixture (Fig. 6B). On the other hand, RAGE showed a signiﬁcant 23% in-
crease in protein level after exposure to Aβ mixture for 24 h, yet cells
treatedwith Aβ40monomers or Aβ42 oligomers did not showany signif-
icant alterations in RAGE protein expression (Fig. 6A and B). Consistent
with the results of TCA degradation assay, there were no signiﬁcant
changes observed in the expression of the Aβ degrading enzymes IDE
and NEP following 24 h exposure to Aβ40 monomers, Aβ42 oligomers
and Aβmixture (Fig. 7A and B).
Fig. 6.Expression of P-gp, LRP1 andRAGE inhCMEC/D3 cells. (A)Western blot analysis of P-gp, LRP1, andRAGEprotein expressions inhCMEC/D3 cells after 24h exposure to controlmedia,
100 nMmonomeric Aβ40, 50 nM Aβ42 oligomers, or Aβmixture of both. (B) Densitometry analyses showed similar expression level of P-gp in all treatment groups, signiﬁcantly higher
RAGE expression and lower LRP1 expression in hCMEC/D3 cells treated with Aβmixture. Data represent mean ± SEM from three independent experiments; ** P b 0.01.
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In AD patients, Aβ peptides coexist in the brain as a heterogeneous
mixture of different Aβ species with different sizes, solubility andFig. 7. (A)Western blot analysis of IDE andNEP protein expression in hCMEC/D3 cells after 24 h
of both. (B) Corresponding densitometry analysis showed that none of the Aβ preparations al
experiments.conformational structures [7]. Although qualitative as well as quantita-
tive changes in Aβ species have a central role in the pathogenesis of AD,
speciﬁc key changes that contribute signiﬁcantly to the development
and progression of AD are still a matter of debate [5,39]. Availableexposure to control media, 100 nMmonomeric Aβ40, 50 nMAβ42 oligomers or Aβmixture
tered the expression of IDE or NEP. Data represent mean ± SEM from three independent
1813H. Qosa et al. / Biochimica et Biophysica Acta 1842 (2014) 1806–1815studies indicate that soluble Aβ pool has high toxicity against neurons
and is highly correlated with the severity of AD [8,11]. Some studies
have identiﬁed speciﬁc individual species in the Aβ soluble pool that ex-
erts signiﬁcant neuronal toxicity, however, the signiﬁcance of these re-
sults remains unclear. It is difﬁcult to attribute Aβ toxicity to a single
species because: 1) it is difﬁcult to prepare highly pure and stable spe-
ciﬁc Aβ assemblies (in vitro or in vivo) due to the unusual behavior of
Aβ peptides in the analytical procedures [40], 2) there is a lack of stan-
dardization of concentrations or puriﬁcation methods, and 3) the more
important issue is that in the brains of AD patients multiple species of
Aβ exist and are expected to change during aging and the course of dis-
ease [41–43]. In addition, physiological, or atmost pathological, concen-
trations of speciﬁc Aβ species are likely to be the most relevant to the
biological situation. Otherwise, it is difﬁcult to compare the intrinsic
toxicity of Aβmixtures to that of speciﬁc species. Instead, studies inves-
tigating the effect of a mixture of Aβ species (at least the known, abun-
dant and pathogenic ones) at physiological and pathological level are
more likely to be informative of the in vivo condition [5].
The intent of this studywas to in vitro investigate the effect of differ-
ent preparations of Aβ on BBB endothelial cells integrity and Aβ40 clear-
ance using hCMEC/D3 cell monolayer as a representative model for the
BBB. Brain endothelial cells, astrocytes and pericytes are involved in
normal function of BBB [44]. While the astrocytes, pericytes and base-
ment membrane play important role in regulating BBB function, only
the capillary endothelium forms the physical barrier separating brain
from blood and control barrier functions of the BBB [44]. Although,
this model is an in vitro model, it expresses many BBB-speciﬁc proper-
ties including stringent restriction of paracellular diffusion of large mol-
ecules [35,45]. Moreover, permeability coefﬁcients of hCMEC/D3 cell
monolayer were well correlated with in vivo permeability coefﬁcients
making this cell line a useful model to study BBB barrier functions [35].Fig. 8. Schematic presentation for a model describing toxic effect of soluble Aβ pool against BBB
cumulated Aβ initiates a cascade of Aβ aggregation to form soluble aggregates of different sizes
tically with monomeric Aβ40 in the form of Aβmixture to disrupt BBB endothelial cells and
formation of a wide range of soluble and insoluble Aβ assemblies enhancing the developmentTotal Aβ40 has been detected in the brains of AD patients at a level
that is 10 times higher than the level of Aβ42. However, the pathological
levels of Aβ40 monomer and Aβ42 oligomers in Aβ soluble pool were
100 nM and in the range of 10 to 100 nM for Aβ40 monomer and Aβ42
oligomers, respectively [33,46]. Therefore, for the purpose of our
study, we used Aβ40 monomer and Aβ42 oligomers at previously identi-
ﬁed pathologically relevant concentrations at 100 nM and in the range
of 10 to 100 nM for Aβ40 monomer and Aβ42 oligomers, respectively.
MTT toxicity studies were initially performed to exclude toxic con-
centrations of Aβ species when added separately or as mixtures. This
is important in order to evaluate the effect of non-toxic concentrations
on hCMEC/D3 monolayer integrity as a cell-based BBB model. Thus, all
subsequent permeability and active transport studies of Aβ40 were con-
ducted at concentrations≤100 nMAβ40monomer and/or≤50 nMAβ42
oligomers.
Our results demonstrated an effect of the soluble Aβ pool, at
nanomolar levels, on the integrity of the hCMEC/D3 model of the BBB
assessed by inulin permeation. While several studies have described
the disruptive effect of Aβ40 oligomers or Aβmonomers (40 or 42) on
BBB permeability [24,29,30,47], the single species of Aβ required high
micromolar concentrations to exert such toxic effect. Unlike these stud-
ies, in the current investigation only Aβmixture that contains both Aβ40
monomers and Aβ42 oligomers, both in nanomolar concentrations, was
able to disrupt the hCMEC/D3monolayer integrity following 24 h treat-
ment, while at the examined concentrations of individual Aβ40 mono-
mers or Aβ42 oligomers had no effect on the monolayer integrity. This
ﬁnding suggested that Aβmixture disrupts the function of tight junction
proteins, thereby enhancing paracellular permeation across the hCMEC/
D3-BBB model. Previous studies showed that treatment of brain endo-
thelial cellswithAβ40monomers, Aβ42monomers or Aβ40 oligomers re-
quired high micromolar concentrations to decrease expression of tightendothelial cells. Faulty clearance of monomeric Aβ results in its brain accumulation. Ac-
and types. In addition to their intrinsic neurotoxicity, soluble Aβ aggregates act synergis-
enhance more Aβ accumulation by halting its clearance across BBB. This accelerates the
of CAA and AD.
1814 H. Qosa et al. / Biochimica et Biophysica Acta 1842 (2014) 1806–1815junction proteins, re-localize tight junction proteins from the plasma
membrane, and enhance paracellular permeation of the culture mono-
layer [29,30]. The mix of Aβ40 monomers and Aβ42 oligomers at
nanomolar concentrations may provoke a more pronounced effect on
tight junction protein expression and localization than the individual
forms, resulting in a leaky BBB that is unable to providemaximal protec-
tion of the brain against circulating neurotoxins.
In spite of leaky hCMEC/D3 monolayer as a result of Aβ mixture
treatment, the transport of 125I-Aβ40was restricted and signiﬁcantly de-
creased following the treatment, suggesting Aβ to disrupt its own clear-
ancemachinery. This ﬁnding conﬁrms Aβ clearance as an active process
mediated by transport proteins, and is consistent with studies reporting
association between the brain load of Aβ and its disposition [48]. This
reduction in the transport of 125I-Aβ40 following Aβmixture treatment
was accompanied by differential effects on the expression of P-gp, IDE
and NEP, LRP1, and RAGE in hCMEC/D3 cells. While cells treatment
with Aβ mixture for 24 h had no effect on P-gp, IDE and NEP expres-
sions, LRP1 and RAGE expressions were signiﬁcantly decreased and in-
creased, respectively. P-gp has been reported to efﬂux Aβ across BBB
toward the blood [14]. Several in vivo and in vitro studies [23–25]
have shown reduction in P-gp expression following treatment with
Aβ monomer or oligomers; however, in the current study this effect
was not observed. This discrepancy could be related to differences in ex-
perimental protocols used including Aβ concentrations (nanomolar vs
micromolar levels) and/or treatment times (24 h vs longer treatment
time up to 96 h).
LRP1, amember of the LDL family receptor, is highly expressed at the
abluminal side of the brain endothelial cells. It mediates transport of Aβ
from the brain to the blood and its expression has been reported to de-
crease with aging and in patients with AD [38]. Findings from the
current study demonstrated that treatment with Aβ mixture down-
regulated LRP1 expression in hCMEC/D3 cells, which is consistent
with previously reported results following in vivo administration of
100 μg Aβ42 monomers over 26 h that caused a signiﬁcant reduction
in LRP1 expression in brain tissue of FVB wild type mice [25], however
with more realistic and relevant concentrations provided by our study.
In contrast to LRP1, Aβmixture up-regulated the cellular expression of
RAGE, which is consistentwith a pattern observed in ADpatients' brains
[17].While the effect of Aβmixture on LRP1 and RAGEwas obvious 24 h
following treatment, the effect of the individual Aβ preparations on
LRP1 and RAGE, or on P-gp, IDE, and NEP would be expected to occur
following a longer exposure time. Our results suggest that LRP1 and
RAGE are more sensitive than P-gp, IDE, and NEP to Aβ changes in the
brain. Given the role of LRP1 and RAGE in efﬂux and inﬂux, respectively,
of Aβ across BBB endothelium, changes in their expressionwould be ex-
pected to alter Aβ transport across the BBB.
Collectively, our in vitro ﬁndings, in addition to previous in vitro and
in vivo studies, suggest that faulty clearance of Aβmay start as a slow
cascade of monomeric Aβ accumulation and aggregation that result in
the formation of a soluble Aβ pool (Aβmixture). Aβmixture possesses
greater disruption effect on the integrity and functionality of the BBB
endothelium compared to either species alone, and enhances rapid ac-
cumulation of Aβ in the brain, which in turn could accelerate the path-
ogenesis of CAA and AD (Fig. 8).5. Conclusion
Study of a soluble Aβ pool containing a mixture of monomeric and
oligomeric Aβ peptide provides a physiologically relevant way to
probe the pathogenesis of AD. While previous in vitro and in vivo stud-
ies investigated the toxicity of speciﬁc Aβ species on the BBB, here, we
provide for the ﬁrst time evidence that amixture of Aβ possess a greater
disruptive effect over and above that of individual Aβ species on the in-
tegrity and function of hCMEC/D3 cells as an in vitro model of BBB. This
concept may also apply to other biological effects of Aβ.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.06.029.
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